Alembic Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about Alembic Pharmaceuticals

Alembic Pharma's US Unit Acquires Utility Therapeutics for $12 Million 5 days ago

Alembic Pharmaceuticals' US unit has acquired Utility Therapeutics for $12 million. This strategic move aims to strengthen Alembic's presence in the US market and expand its portfolio of urinary tract infection (UTI) treatments. The acquisition is expected to broaden Alembic's product range, enhance its position in the US pharmaceutical market, and potentially increase revenue streams from UTI drug segments.

Alembic Pharma Secures USFDA Approval for $29 Million Market Opportunity 8 days ago

Alembic Pharmaceuticals Secures Establishment Inspection Report for API-III Facility Jun 18, 2025

Alembic Pharmaceuticals Facility Receives 4 USFDA Observations Following CGMP Inspection Jun 02, 2025

Alembic Pharma Stock Rises on FDA Approval for Blood Cancer Drug May 30, 2025

More news about Alembic Pharmaceuticals

30May 25

Alembic Pharma Secures USFDA Approval for Bosutinib Tablets

Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (USFDA) for its Bosutinib Tablets. The approved product, used in treating certain types of leukemia, has reported U.S. sales of $291.00 million. This approval enhances Alembic's product portfolio and opens up opportunities in the oncology segment.

15May 25

Alembic Pharmaceuticals Secures USFDA Approval for Rivaroxaban Tablets

Alembic Pharmaceuticals has received final approval from the USFDA for its Rivaroxaban Tablets. This anticoagulant medication, used to treat and prevent blood clots, has a US market size of approximately $445.00 million. The approval enhances Alembic's presence in the US generic drug market and demonstrates its capability in developing complex generic formulations.

07May 25

Alembic Pharma Outlines R&D Expense Plans for Coming Years

Alembic Pharmaceuticals has disclosed its R&D expense projections for the upcoming fiscal years. The company plans to invest ₹500 crores in FY 2024-25 and ₹600-650 crores in FY 2025-26. This increased spending signals a strong commitment to innovation, potential market expansion, and a long-term growth strategy. The move aligns with industry trends of focusing on R&D to maintain competitiveness in the pharmaceutical sector.

07May 25

Alembic Pharma Eyes EBITDA Margin Boost Amid Optimized R&D Spending

Alembic Pharmaceuticals anticipates improved EBITDA margins in upcoming quarters and years, driven by optimized R&D spending. This outlook comes despite recent financial results showing mixed performance, with Q4 FY2024 revenue up 6.88% YoY but EBITDA and net profit declining significantly. The company's EBITDA margin contracted from 19.94% to 11.61%. Management's strategy focuses on balancing innovation with profitability through R&D optimization, aiming to enhance overall profitability and competitive position.

06May 25

Alembic Pharma Sets Ambitious Global Expansion Targets for FY26

Alembic Pharmaceuticals has announced plans to launch over 40 new products across international markets including the EU, Canada, Australia, and South Africa by FY2026. The strategy focuses on diversifying product portfolio across various dosage forms and emphasizes timely market entry. This move aims to strengthen Alembic's global presence, expand its market footprint, and drive long-term growth in the international pharmaceutical landscape.

06May 25

Alembic Pharmaceuticals: Q4 Profit Down 12%, Revenue Up, ₹11 Dividend Proposed

Alembic Pharmaceuticals announced its Q4 FY23 results, showing a 16.70% YoY increase in revenue to ₹1,769.60 crore, but an 11.80% YoY decrease in net profit to ₹157.00 crore. EBITDA grew 4.60% to ₹272.00 crore, with the EBITDA margin narrowing to 15.40%. The company proposed a dividend of ₹11.00 per share for FY23.

02May 25

Alembic Pharmaceuticals Secures FDA Approval for Generic Heart Attack Prevention Drug

Alembic Pharmaceuticals has received FDA approval for its generic version of Ticagrelor Tablets. The 90 mg strength received final approval, while the 60 mg strength got tentative approval. This generic is equivalent to AstraZeneca's Brilinta Tablets. The estimated market size for 90 mg and 60 mg strengths is US$ 1,062.00 million and US$ 242.00 million respectively. Ticagrelor tablets are used for various cardiovascular conditions. This approval brings Alembic's total ANDA approvals from FDA to 222, including 197 final and 25 tentative approvals.

02May 25

Alembic Pharmaceuticals Secures USFDA Approval for Ticagrelor Tablets

Alembic Pharmaceuticals has received final approval from the USFDA for its Ticagrelor tablets, an antiplatelet medication used to prevent blood clots. This approval allows Alembic to enter the U.S. market for this product, which has annual sales of approximately USD 1.00 billion. The approval marks a significant milestone in Alembic's U.S. market expansion strategy and could potentially boost its revenue from U.S. operations.

26Apr 25

Alembic Pharma Boosts Production Capacity with New ₹205.00 Crore Facility in Madhya Pradesh

Alembic Pharmaceuticals Limited has launched a new formulation manufacturing facility in Pithampur, Madhya Pradesh, with an investment of ₹205 crore. The facility, operational from April 26, 2025, aims to support business expansion and bring third-party production in-house. Financed through internal accruals and borrowings, this strategic move is expected to enhance the company's production capabilities and operational efficiency.

17Apr 25

Alembic Pharmaceuticals Secures FDA Approval for Carbamazepine Tablets

Alembic Pharmaceuticals has received final FDA approval for Carbamazepine Tablets USP, 200 mg, an anticonvulsant and pain treatment medication. The drug enters a market with an estimated size of $32.00 million for the 12 months ending December 2024. This approval strengthens Alembic's U.S. market presence and expands its product portfolio.

01Apr 25

Alembic Pharmaceuticals Secures USFDA Approval for Pantoprazole Sodium Injection

Alembic Pharmaceuticals has received final USFDA approval for Pantoprazole Sodium for Injection, 40 mg/vial. The drug, equivalent to Wyeth's Protonix I.V., is used to treat GERD and other gastric conditions. The estimated market size for this product is $48 million. This approval brings Alembic's total ANDA approvals to 221, including 195 final and 26 tentative approvals.

24Mar 25

Alembic Pharma's API-III Facility Clears USFDA Inspection with Flying Colors

Alembic Pharmaceuticals' API-III facility in Karakhadi successfully cleared a USFDA inspection with no Form 483 observations. This outcome demonstrates the facility's high-quality standards and regulatory compliance, potentially boosting market confidence and providing a competitive advantage in the pharmaceutical industry.

21Mar 25

Alembic Pharmaceuticals Clears USFDA Inspection at Karakhadi API Facility

Alembic Pharmaceuticals Limited successfully completed a USFDA GMP inspection at its API-III facility in Karakhadi, Gujarat, from March 17-21, 2025. The inspection concluded with no Form 483 observations, indicating high compliance with USFDA standards. This outcome demonstrates the company's commitment to quality control and regulatory adherence, potentially boosting market confidence and ensuring operational continuity.

18Mar 25

Alembic Pharmaceuticals Expands Global Footprint with New US Subsidiary

Alembic Pharmaceuticals has established a new wholly-owned subsidiary, Alembic Lifesciences Inc, in Delaware, USA, through its subsidiary Alembic Global Holding SA. The company also announced the appointment of Ms. Geeta Goradia as an Independent Director, approved by shareholders with 94.70% votes in favor.

17Mar 25

Alembic Pharmaceuticals Expands US Presence with New Subsidiary

Alembic Pharmaceuticals Limited has incorporated a new wholly-owned subsidiary, Alembic Lifesciences Inc., in Delaware, USA on March 13, 2025. The subsidiary, operating under Alembic Global Holding SA, aims to strengthen the company's presence in the US pharmaceutical market. While specific operational details are undisclosed, the move is likely intended to enhance research capabilities, expand product portfolio, and improve US distribution. Alembic Global Holding SA will make a remittance for 100% shareholding, though the investment amount is unspecified.

10Mar 25

Alembic Pharmaceuticals Receives Form 483 After USFDA Inspection

Alembic Pharmaceuticals' bioequivalence facility in Vadodara, Gujarat, underwent a USFDA inspection from March 3 to March 7. The inspection concluded with a Form 483 containing one procedural observation. This outcome is relatively positive for the company, as it suggests a minor issue that may be addressable without significant operational disruption. The bioequivalence facility is crucial for Alembic's generic drug development process. The company is expected to respond with a plan to address the observation, which will be important for maintaining regulatory compliance and ensuring smooth operations.

07Mar 25

Alembic Pharmaceuticals Receives Form 483 After USFDA Inspection at Bioequivalence Facility

Alembic Pharmaceuticals' bioequivalence facility in Vadodara underwent a USFDA inspection from March 3-7, 2025, resulting in a Form 483 with one procedural observation. The company has committed to providing a comprehensive response within the stipulated timeframe and maintains its dedication to high-quality standards and compliance.